DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Hemophilia A and B Recombinant Factor Replacement Therapy - Japan Drug Forecast and Market Analysis to 2024" report to their offering.
Japan's total market for recombinant hemophilia treatments is projected to grow very modestly. However, the overall prevalence of hemophilia A and B in Japan is expected to decline over the forecast period due to the declining population and birth rate. In addition, we believe that opportunities for premium pricing will be limited in Japan, further constraining the growth of the Japanese hemophilia market.
- Overview of Hemophilia A and B including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in Japan including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in Japan from 2014-2024.
- Analysis of the impact of key events as well the drivers and restraints affecting Japan Hemophilia A and B market.
Key Topics Covered:
1 Tables & Figures
3 Disease Overview
4 Disease Management
5 Competitive Assessment
5.2 Strategic Competitive Assessment
5.3 Product Profiles - Hemophilia A
5.4 Product Profiles - Hemophilia B
5.5 Product Profiles - Hemophilia A and B with Inhibitors
6 Unmet Need and Opportunity
6.2 Opportunity Analysis
6.3 Unmet Needs Gap Analysis
7 Pipeline Assessment
7.2 Late-Stage Development Candidates - Hemophilia A
7.3 Late-Stage Development Candidates - Hemophilia B
7.4 Late-Stage Development Candidates - Hemophilia A and B Bypassing Agents (Patients with Inhibitors)
7.5 Promising Drugs in Early-Stage Development
8 Market Outlook
For more information visit http://www.researchandmarkets.com/research/9cmkr3/hemophilia_a_and